Hepatic and renal toxicities of indomethacin acid, salt form and complexed forms with hydroxypropyl-β-cyclodextrin on Wistar rats after oral administration

Fundamental and Clinical Pharmacology

Volumn 25, Issue 5, 2011, Pages 599-607

  Ribeiro Rama, Ana Cristina ^a   Figueiredo, Isabel Vitória ^a   Veiga, Francisco José ^a   Castel Branco, Maria Margarida ^a   Cabrita, António M Silvério ^b   Caramona, Maria Margarida ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Histopathology; Hydroxypropyl cyclodextrin; Indomethacin; Kidney; Liver; Toxicity

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 4 CHLOROBENZOIC ACID; INDOMETACIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; FEMALE; FREEZING; GASTROINTESTINAL TRACT; HISTOPATHOLOGY; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAY DRYING; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; EXCIPIENTS; FEMALE; FREEZE DRYING; GASTROINTESTINAL TRACT; INDOMETHACIN; KIDNEY; LIVER; MALE; MODELS, ANIMAL; RANDOM ALLOCATION; RATS; RATS, WISTAR; STOMACH DISEASES;

EID: 80052910376     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00887.x     Document Type: Article

References (42)

1. Liversidge G.G., Dent J., Eickhoff W.M. Influence of indomethacin amphoteric gel on gastric ulcerogenicity and absorption of indomethacin in rats. Pharm. Res. (1989) 6 44-48.
2. Bulbena O., Escolar D., Navarro C. et al. Gastroprotective effect of zinc acexamate against damage induced by nonsteroidal anti-inflammatory drugs: a morphological study. Dig. Dis. Sci. (1993) 38 730-739.
3. Skeljo M.V., Giraud A.S., Yeomans N.D. Gastric mucosal damage induced by nonsalicylate nonsteroidal anti-inflammatory drugs in rats is mediated systemically. Dig. Dis. Sci. (1993) 38 2038-2042.
4. Hammerman C., Kaplan M. Comparative tolerability of pharmacological treatments for patent ductus arteriosus. Drug Saf. (2001) 24 537-551.
5. Richardson D.A. Woman with an extremely premature newborn. J. Am. Med. Assoc. (2001) 286 1498-1505.
6. Ribeiro Rama A.C., Veiga F., Figueiredo I.V. et al. [Biopharmaceutical aspects of drug formulation for neonatology: rational for indomethacin's complexation with hydroxypropyl-b-cyclodextrin to treat patent ductus arteriosus]. Rev. Bras. Cienc. Farm. (2005) 41 281-299.
7. Backensfeld T., Müller B.W., Wiese M. et al. Effect of cyclodextrin derivatives on indomethacin stability in aqueous solution. Pharm. Res. (1990) 7 484-490.
8. Djedaïni F., Lin S.Z., Perly B. et al. High-field nuclear magnetic resonance techniques for the investigation of a β-cyclodextrin: indomethacin inclusion complex. J. Pharm. Sci. (1990) 79 643-646.
9. Redenti E., Szente L., Szejtli J. Cyclodextrin complexes of salts of acidic drugs: thermodynamic properties, structural features, and pharmaceutical applications. J. Pharm. Sci. (2001) 90 979-986.
10. Ribeiro Rama A.C. [Indomethacin gastric toxicity reduction by complexation with hydroxypropyl-ß-cyclodextrin]. Master Thesis, Faculdade de Farmácia da Universidade de Coimbra, Coimbra, 2004.
11. Ribeiro Rama A.C., Veiga F., Figueiredo I.V. et al. [Inclusion compounds of indomethacin with hydroxypropyl-β-cyclodextrin. Dissolution profile and partition coefficient evaluation]. Rev. Bras. Cienc. Farm. (2006) 42 59-68.
12. Cabral-Marques H. Applications of cyclodextrins: thermodynamic aspects of cyclodextrin complexes. Rev. Port. Farm. (1994) 44 85-96.
13. Ribeiro Rama A.C., Figueiredo I.V., Veiga F. et al. Evaluation of gastric toxicity of indomethacin acid, salt form and complexed forms with hydroxypropyl-ß-cyclodextrin on Wistar rats. Histopathologic analysis. Fundam. Clin. Pharmacol. (2009) 23 747-755.
14. Biscarini L. Non-steroidal anti-inflammatory drugs, in: Dukes M.N.G., Aronson J.K., Meyler's side effects of drugs, 14th edn, Elsevier, Amsterdam, 2000a, p. 280.
15. Biscarini L. Non-steroidal anti-inflammatory drugs, in: Dukes M.N.G., Aronson J.K., Meyler's sideeffects of drugs, 14th edn, Elsevier, Amsterdam, 2000b, p. 281.
16. Chamaa N.S., Mosig D., Drukker A. et al. The renal hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr. Res. (2000) 48 600-605.
17. Cuzzolin L., Dalcerè M., Fanos V. NSAID-Induced nephrotoxicity from the fetus to the child. Drug Saf. (2001) 24 9-18.
18. Fowlie P.W. Prophylactic indomethacin: systematic review and meta-analysis. Arch. Dis. Child. (1996) 74 F81-F87.
19. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. (2002) 22 137-144.
20. Ojala R., Ala-Houhala M., Ahonen S. et al. Renal follow-up of premature infants with and without perinatal indomethacin exposure. Arch. Dis. Child. Fetal Neonatal Ed. (2001) 84 F28-F33.
21. Pezzati M., Vangi V., Biagiotti R. et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J. Pediatr. (1999) 135 733-738.
22. Romagnoli C., Zecca E., Papacci P. et al. Furosemide does not prevent indomethacin-induced renal side effects in preterm infants. Clin. Pharmacol. Ther. (1997) 62 181-186.
23. Zimmerman H.J. Drug-induced liver disease, in: Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, 2nd edn, Lippincott Williams & Wilkins, Philadelphia, 1999a, pp. 436-439.
24. Zimmerman H.J. Drugs to treat rheumatic/musculospastic disease, in: Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, 2nd edn, Lippincott Williams & Wilkins, Philadelphia, 1999b, pp. 518-527.
25. Kaplowitz N. Mechanisms of liver cell injury. J. Hepatol. (2000) 32(suppl. 1) 39-47.
26. Cappell M.S., Kozicky O., Competiello L.S. Indomethacin-associated cholestasis. J. Clin. Gastroenterol. (1988) 10 445-447.
27. Shivakumar C., Jacob G. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. (2002) 22 169-183.
28. LaFramboise W.A., Bombach K.L., Pogozelski A.R. et al. Hepatic gene expression response to acute indomethacin exposure. Mol. Diagn. Ther. (2006) 10 187-196.
29. Brion L.P., Campbell D.E. Furosemide in indomethacin-treated infants: systematic review and meta-analysis. Pediatr. Nephrol. (1999) 13 212-218.
30. Dinchuk J.E., Car B.D., Focht R.J. et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (1995) 378 406-409.
31. Kent A.L., Maxwell L.E., Koina M.E. et al. Renal glomeruli and tubular injury following indomethacin, ibuprofen, and gentamicin exposure in a neonatal rat model. Pediatr. Res. (2007) 62 307-312.
32. Ou Y.C., Yang C.R., Cheng C.L. et al. Indomethacin causes renal epithelial cell injury involving Mcl-1 down-regulation. Biochem. Biophys. Res. Commun. (2009) 380 531-536.
33. Somasundaram S., Rafi S., Hayllar J. et al. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut (1997) 41 344-353.
34. Ammoury N., Dubrasquet M., Fessi H. et al. Indomethacin-loaded poly (D, L-lactide) nanocapsules: protection from gastrointestinal ulcerations and anti-inflammatory activity evaluation in rats. Clin. Mater. (1993) 13 121-130.
35. Harman R.E., Meisinger M.A., Davis G.E. et al. The metabolites of indomethacin, a new anti-inflammatory drug. J. Pharmacol. Exp. Ther. (1964) 143 215-220.
36. Ogiso T., Iwaki M., Kinoshita T. et al. Pharmacokinetics of indomethacin octyl ester (prodrug) and indomethacin produced from the prodrug. J. Pharm. Sci. (1994) 83 34-37.
37. Suzuki T., Suganuma T., Shimizu R. et al. Relationship between pharmacokinetics and the analgesic effect of indomethacin in the rat. Biol. Pharm. Bull. (1997) 20 438-442.
38. Krasna I.H., Lee R.T. Allopurinol protects the bowel from necrosis caused by indomethacin and temporary intestinal ischemia in mice. J. Pediatr. Surg. (1993) 28 1175-1177.
39. Lin S.Z., Wouessidjewe D., Poelman M.-C. et al. In vivo evaluation of indomethacin/cyclodextrin complexes: gastrointestinal tolerance and dermal anti-inflammatory activity. Int. J. Pharm. (1994) 106 63-67.
40. Ammoury N., Fessi H., Devissaguet J.P. et al. Rôle protecteur des nanocapsules vis-à-vis des lésions de la muqueuse gastrique produites par l'indométacine chez le rat à pylore lié. S.T.P. Pharma. (1989) 5 537-540.
41. Dacie J.V., Lewis S.M. Preparation and staining methods for blood and bone-marrow films, in: Dacies J.V., Lewis S.M., Practical haemetology, 7th edn. Churchill Livingstone, New York, 1991, pp. 75-85.
42. Wong J., Loewenthal J. Chronic gastric ulcer in the rat produced by wounding at the fundo-antral junction. Gastroenterology (1976) 71 416-420.